<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7904301</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4537</journal-id>
<journal-id journal-id-type="nlm-ta">J Autism Dev Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">J Autism Dev Disord</journal-id>
<journal-title-group>
<journal-title>Journal of autism and developmental disorders</journal-title>
</journal-title-group>
<issn pub-type="ppub">0162-3257</issn>
<issn pub-type="epub">1573-3432</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26754479</article-id>
<article-id pub-id-type="pmc">5362964</article-id>
<article-id pub-id-type="doi">10.1007/s10803-015-2694-0</article-id>
<article-id pub-id-type="manuscript">NIHMS850979</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Assessment of cognitive outcome measures in teenagers with 15q13.3 microdeletion syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Crutcher</surname>
<given-names>Emeline</given-names>
</name>
<degrees>B.S.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ali</surname>
<given-names>May</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harrison</surname>
<given-names>John</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sovago</surname>
<given-names>Judit</given-names>
</name>
<degrees>M.D., PhD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gomez-Mancilla</surname>
<given-names>Baltazar</given-names>
</name>
<degrees>M.D., PhD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schaaf</surname>
<given-names>Christian P.</given-names>
</name>
<degrees>M.D., PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">⌧</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA</aff>
<aff id="A2"><label>2</label>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA</aff>
<aff id="A3"><label>3</label>Jan and Dan Duncan Neurological Research Institute, Texas Children’s Hospital, Houston, TX, USA</aff>
<aff id="A4"><label>4</label>Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands</aff>
<aff id="A5"><label>5</label>Novartis Pharmaceutical Corporation, Basel, Switzerland</aff>
<author-notes>
<corresp id="FN1"><label>⌧</label>to whom correspondence should be addressed: Christian Schaaf, MD, PhD; Jan and Dan Duncan Neurological Research Institute; 1250 Moursund St, Suite 1325; Houston, TX 77030, USA. Phone: (832) 822-4280. Fax: <email>schaaf@bcm.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>23</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>46</volume>
<issue>4</issue>
<fpage>1455</fpage>
<lpage>1463</lpage>
<!--elocation-id from pubmed: 10.1007/s10803-015-2694-0-->
<abstract>
<p id="P1">15q13.3 microdeletion syndrome causes a spectrum of cognitive disorders, including intellectual disability and autism. We aimed to determine if any or all of three cognitive tests (the KiTAP, CogState, and Stanford-Binet) are suitable for assessment of cognitive function in affected individuals. These three tests were administered to ten individuals with 15q13.3 microdeletion syndrome (14–18 years of age), and the results were analyzed to determine feasibility of use, potential for improvement, and internal consistency. It was determined that the KiTAP, CogState, and Stanford-Binet are valid tests of cognitive function in 15q13.3 microdeletion patients. Therefore, these tests may be considered for use as objective outcome measures in future clinical trials, assessing change in cognitive function over a period of pharmacological treatment.</p>
</abstract>
<kwd-group>
<kwd>neuropsychiatric disease</kwd>
<kwd>autism</kwd>
<kwd>intellectual disability</kwd>
<kwd>cognitive tests</kwd>
<kwd>cognitive function</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>